Veracyte (VCYT) News Today $39.21 -1.84 (-4.47%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Analysts Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $42.00February 21 at 1:19 AM | americanbankingnews.comVeracyte Inc (VCYT) Announces Participation in Key Investor ConferencesFebruary 20 at 9:13 PM | gurufocus.com8,074 Shares in Veracyte, Inc. (NASDAQ:VCYT) Bought by Convergence Investment Partners LLCConvergence Investment Partners LLC acquired a new position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 8,074 shares of the biotechnology company'sFebruary 20 at 4:45 AM | marketbeat.comVeracyte to Participate in Upcoming Investor ConferencesFebruary 19 at 5:05 PM | businesswire.comRice Hall James & Associates LLC Sells 31,575 Shares of Veracyte, Inc. (NASDAQ:VCYT)Rice Hall James & Associates LLC reduced its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 24.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,615 shares of the biotechnoloFebruary 19 at 5:23 AM | marketbeat.comVeracyte (NASDAQ:VCYT) Lowered to "Hold" Rating by StockNews.comFebruary 19 at 1:57 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a holdFebruary 18 at 2:14 AM | marketbeat.comVeracyte (NASDAQ:VCYT) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Veracyte from a "buy" rating to a "hold" rating in a report on Tuesday.February 18 at 1:16 AM | marketbeat.comVeracyte (VCYT) Expected to Announce Earnings on MondayVeracyte (NASDAQ:VCYT) will be releasing earnings after the market closes on Monday, February 24. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662371)February 17, 2025 | marketbeat.comNew Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer ResearchFebruary 14, 2025 | businesswire.comBest Momentum Stocks To Buy For February 13thFebruary 13, 2025 | benzinga.comVeracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU SymposiumFebruary 12, 2025 | finance.yahoo.comArtisan Partners Limited Partnership's Strategic Acquisition in Veracyte IncFebruary 12, 2025 | gurufocus.comVeracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU SymposiumFebruary 11, 2025 | tmcnet.comVeracyte announces 17 Decipher-focused abstracts at 2025 ASCO GUFebruary 11, 2025 | markets.businessinsider.comVeracyte (NASDAQ:VCYT) Raised to "Buy" at StockNews.comStockNews.com upgraded Veracyte from a "hold" rating to a "buy" rating in a research report on Monday.February 10, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Has $98.74 Million Stock Position in Veracyte, Inc. (NASDAQ:VCYT)Sumitomo Mitsui Trust Group Inc. cut its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 9.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,493,377 shares of the biotechnology company's stFebruary 9, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Trading Down 7.1% - What's Next?Veracyte (NASDAQ:VCYT) Stock Price Down 7.1% - What's Next?February 7, 2025 | marketbeat.comRebecca Chambers Sells 527 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockFebruary 6, 2025 | insidertrades.comVeracyte CFO Rebecca Chambers sells $23,108 in stockFebruary 5, 2025 | msn.comVeracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 SharesVeracyte, Inc. (NASDAQ:VCYT - Get Free Report) CFO Rebecca Chambers sold 527 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $43.85, for a total transaction of $23,108.95. Following the completion of the sale, the chief financial officer now owns 113,510 shares in the company, valued at approximately $4,977,413.50. This trade represents a 0.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.February 5, 2025 | marketbeat.comNew Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder CancerFebruary 5, 2025 | finance.yahoo.comVeracyte Inc (VCYT) Unveils Promising Data on Decipher Bladder Genomic Subtyping ClassifierFebruary 5, 2025 | gurufocus.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Jennison Associates LLCJennison Associates LLC raised its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 116.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 833,754 shares of the biotechnology company's stock after acquFebruary 5, 2025 | marketbeat.comVeracyte Inc (VCYT) Announces Upcoming Release of Q4 and Full-Year 2024 Financial ResultsFebruary 4, 2025 | gurufocus.comVeracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025February 4, 2025 | businesswire.comBaader Bank Aktiengesellschaft Invests $262,000 in Veracyte, Inc. (NASDAQ:VCYT)Baader Bank Aktiengesellschaft bought a new stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,621 shares of the biotechnology company's stockJanuary 31, 2025 | marketbeat.comVeracyte’s Growth Potential and Innovation Drive Buy RatingJanuary 30, 2025 | markets.businessinsider.comVeracyte Stock Soars to 52-Week High, Reaching $46.12January 30, 2025 | msn.comVeracyte (NASDAQ:VCYT) Sets New 52-Week High on Analyst UpgradeVeracyte (NASDAQ:VCYT) Hits New 1-Year High on Analyst UpgradeJanuary 30, 2025 | marketbeat.com3 US Stocks Estimated To Be Undervalued By Up To 49.9% Presenting An OpportunityJanuary 29, 2025 | finance.yahoo.comVeracyte stock price target raised to $51 at NeedhamJanuary 29, 2025 | msn.comNeedham & Company LLC Raises Veracyte (NASDAQ:VCYT) Price Target to $51.00Needham & Company LLC raised their price objective on Veracyte from $44.00 to $51.00 and gave the company a "buy" rating in a research note on Wednesday.January 29, 2025 | marketbeat.comStockNews.com Downgrades Veracyte (NASDAQ:VCYT) to HoldStockNews.com cut Veracyte from a "buy" rating to a "hold" rating in a report on Tuesday.January 28, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Exchange Traded Concepts LLCExchange Traded Concepts LLC lessened its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 23.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 69,429 shares of the biotechnology company's stock afJanuary 26, 2025 | marketbeat.comAEGON ASSET MANAGEMENT UK Plc Sells 39,048 Shares of Veracyte, Inc. (NASDAQ:VCYT)AEGON ASSET MANAGEMENT UK Plc lowered its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 675,801 shares of the biotechnology company's stock after selling 39,048 shares durJanuary 25, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of "Moderate Buy" from AnalystsVeracyte, Inc. (NASDAQ:VCYT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and sevenJanuary 24, 2025 | marketbeat.comAMI Asset Management Corp Lowers Stake in Veracyte, Inc. (NASDAQ:VCYT)AMI Asset Management Corp lessened its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 43.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,926 shares of the biotechnology compaJanuary 21, 2025 | marketbeat.comLegal Advantage Investments Inc. Purchases Shares of 6,306 Veracyte, Inc. (NASDAQ:VCYT)Legal Advantage Investments Inc. purchased a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,306 shares of the biotechnology company's stock, vJanuary 21, 2025 | marketbeat.comAvanza Fonder AB Takes $1.38 Million Position in Veracyte, Inc. (NASDAQ:VCYT)Avanza Fonder AB purchased a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 34,818 shares of the biotechnology company's stock, valued at approximately $1,379,000. Other institutiJanuary 19, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Veracyte from a "hold" rating to a "buy" rating in a research note on Friday.January 17, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. cut its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 79.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 34,745 shares of the biotechnology company's stock after selling 136,089 shares during the period. Harbor CapJanuary 13, 2025 | marketbeat.comCatherine Wood's Strategic Reduction in Veracyte Inc SharesJanuary 10, 2025 | gurufocus.comVeracyte, Inc. (NASDAQ:VCYT) Has Found A Path To ProfitabilityJanuary 10, 2025 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Diversified Trust CoDiversified Trust Co reduced its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 47.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,049 shares of the biotechnology company's stock after selling 1January 10, 2025 | marketbeat.comKarin Eastham Sells 10,000 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockJanuary 7, 2025 | insidertrades.comInsider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells 10,000 Shares of StockVeracyte, Inc. (NASDAQ:VCYT - Get Free Report) Director Karin Eastham sold 10,000 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $40.30, for a total value of $403,000.00. Following the completion of the transaction, the director now directly owns 18,497 shares of the company's stock, valued at approximately $745,429.10. This trade represents a 35.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.January 6, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Position Reduced by Principal Financial Group Inc.Principal Financial Group Inc. reduced its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 32.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,486 shares of the biotJanuary 5, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by BrokeragesVeracyte, Inc. (NASDAQ:VCYT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and sevenDecember 30, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Short Interest UpdateVeracyte, Inc. (NASDAQ:VCYT - Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 2,550,000 shares, a decrease of 14.1% from the November 30th total of 2,970,000 shares. Based on an average trading volume of 782,700 shares, the days-to-cover ratio is currently 3.3 days.December 29, 2024 | marketbeat.com Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Media Mentions By Week VCYT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VCYT News Sentiment▼0.570.60▲Average Medical News Sentiment VCYT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VCYT Articles This Week▼95▲VCYT Articles Average Week Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Guardant Health News Today Option Care Health News Today RadNet News Today BrightSpring Health Services News Today Sotera Health News Today Surgery Partners News Today LifeStance Health Group News Today Privia Health Group News Today Concentra Group Holdings Parent News Today Teladoc Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VCYT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
